Connect with us

Technology

IAS Reports Fourth Quarter and Full Year 2023 Financial Results

Published

8 months ago

on

Fourth quarter revenue increased 14% to $134.3 million

Fourth quarter net income of $10.2 million at an 8% margin; fourth quarter adjusted EBITDA increased 19% to $47.5 million at a 35% margin

NEW YORK, Feb. 27, 2024 /PRNewswire/ — Integral Ad Science Holding Corp. (Nasdaq: IAS), a leading global media measurement and optimization platform, today announced financial results for the fourth quarter and full year ended December 31, 2023.

“We ended 2023 with strong fourth quarter performance across optimization and measurement with revenue growth of 16% and 18%, respectively,” said Lisa Utzschneider, CEO of IAS. “Social media revenue increased 37% in the fourth quarter as marketers trusted IAS to maximize their advertising spend globally, particularly in short-form video. In 2024, we will continue to invest in data science and innovate with AI to empower marketers with actionable data to drive superior results. We expect to deliver double-digit revenue growth for the full year.”  

Fourth Quarter 2023 Financial Highlights

Total revenue was $134.3 million, a 14% increase compared to $117.4 million in the prior-year period.Optimization revenue was $63.6 million, a 16% increase compared to $55.1 million in the prior-year period.Measurement revenue was $52.6 million, an 18% increase compared to $44.7 million in the prior-year period.Publisher revenue was $18.1 million, a 2% increase compared to $17.6 million in the prior-year period.International revenue, excluding the Americas, was $43.3 million, a 16% increase compared to $37.3 million in the prior-year period, or 32% of total revenue for the fourth quarter of 2023.Gross profit was $106.0 million, an 11% increase compared to $95.5 million in the prior-year period. Gross profit margin was 79% for the fourth quarter of 2023.Net income was $10.2 million, or $0.06 per basic and diluted share, compared to $11.5 million, or $0.07 per basic and diluted share, in the prior-year-period. Net income margin was 8% for the fourth quarter of 2023.Adjusted EBITDA* was $47.5 million, a 19% increase compared to $40.0 million in the prior-year period. Adjusted EBITDA* margin was 35% for the fourth quarter of 2023.

Full Year 2023 Financial Highlights

Total revenue was $474.4 million, a 16% increase compared to $408.3 million in the prior year.Optimization revenue was $224.5 million, an 18% increase compared to $190.6 million in the prior year.Measurement revenue was $186.0 million, a 20% increase compared to $154.9 million in the prior year.Publisher revenue was $63.8 million, a 2% increase compared to $62.8 million in the prior year.International revenue, excluding the Americas, was $146.8 million, a 14% increase compared to $129.1 million in the prior year, or 31% of total revenue for the full year 2023.Gross profit was $375.0 million, a 13% increase compared to $332.6 million in the prior year. Gross profit margin was 79% for the full year 2023.Net income was $7.2 million, or $0.04 per diluted share, compared to $15.4 million, or $0.10 per basic and diluted share, in the prior year. Net income margin was 2% for the full year 2023.Adjusted EBITDA* was $159.5 million, a 26% increase compared to $126.6 million in the prior year. Adjusted EBITDA* margin was 34% for the full year 2023.Cash and cash equivalents were $124.8 million at December 31, 2023.

Recent Business Highlights

Meta Expansion – In February, IAS announced the availability of its AI-driven Total Media Quality (TMQ) brand safety and suitability measurement product across Facebook and Instagram Feed and Reels. IAS’s new post-bid brand safety and suitability expansion with Meta gives advertisers increased transparency into whether their campaigns are appearing next to safe and suitable content.IAS MRC Continuing Accreditation for Measurement of Meta Platforms – In January, IAS received continuing accreditation from the MRC for viewability measurement of Meta, including impressions and two-second video viewability, on Facebook Feed and Instagram Feed and Stories.YouTube TMQ Expansion – During the fourth quarter, IAS expanded its partnership to YouTube Shorts to offer its brand safety and suitability measurement product to advertisers for YouTube Shorts inventory, as part of its existing Total Media Quality for YouTube product suite.X Expansion – In February, IAS expanded its partnership with X to all U.S. advertisers. IAS classifies all vertical video ad adjacencies for brand safety and suitability aligned to the GARM framework, giving advertisers maximum control over where their ads appear on the X vertical video feed.Quality Attention Expansion – In January, IAS announced the general availability of its Quality Attention measurement product. Quality Attention uses advanced machine learning technology, actionable data from Lumen Research’s eye-tracking technology, and a variety of signals obtained as part of IAS’s core technology.

Financial Outlook

“We reported profitable growth in the fourth quarter with a 14% revenue increase at a 35% adjusted EBITDA* margin,” said Tania Secor, CFO of IAS. “As we move through 2024, we expect to ramp both revenue growth and profitability from forecasted first quarter levels as we expand availability and customer adoption of new products. We also plan to maintain our strong financial profile and healthy balance sheet.”

IAS is introducing the following financial outlook for the first quarter and full year 2024:

First Quarter Ending March 31, 2024:

Total revenue of $111 million to $113 millionAdjusted EBITDA* of $28 million to $30 million

Year Ending December 31, 2024:

Total revenue of $530 million to $540 millionAdjusted EBITDA* of $171 million to $179 million

* See “Supplemental Disclosure Regarding Non-GAAP Financial Information” section herein for an explanation of Non-GAAP measures. IAS is unable to provide a reconciliation for forward-looking guidance of Adjusted EBITDA to net income (loss), the most closely comparable GAAP measure, because certain material reconciling items, such as depreciation and amortization, interest expense, income tax expense (benefit), restructuring and severance costs, and acquisition and integration costs, cannot be estimated due to factors outside of IAS’s control and could have a material impact on the reported results. However, IAS estimates stock-based compensation expense for the first quarter of 2024 in the range of $14 million to $16 million and for the full year 2024 in the range of $72 million to $76 million. A reconciliation is not available without unreasonable effort.

 

INTEGRAL AD SCIENCE HOLDING CORP.

CONSOLIDATED BALANCE SHEETS

 

(IN THOUSANDS, EXCEPT SHARE DATA)

December 31, 2023

December 31, 2022

ASSETS

Current assets:

Cash and cash equivalents

$      124,759

$        86,877

Restricted cash

54

45

Accounts receivable, net

74,609

67,884

Unbilled receivables

46,548

41,550

Prepaid expenses and other current assets

18,959

24,761

Due from related party

—

29

Total current assets

264,929

221,146

Property and equipment, net

3,769

2,412

Internal use software, net

40,301

23,642

Intangible assets, net

178,908

217,558

Goodwill

675,282

674,094

Operating lease right-of-use assets, net

21,668

22,787

Deferred tax asset, net

2,465

2,020

Other long-term assets

4,402

5,024

Total assets

$   1,191,724

$   1,168,683

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Accounts payable and accrued expenses

$        72,232

$        60,799

Operating lease liabilities, current

9,435

6,749

Due to related party

121

122

Deferred revenue

682

99

Total current liabilities

82,470

67,769

Deferred tax liability, net

20,367

45,495

Long-term debt

153,725

223,262

Operating lease liabilities, non-current

19,523

22,875

Other long-term liabilities

6,183

1,066

Total liabilities

282,268

360,467

Commitments and Contingencies

Stockholders’ Equity

Preferred Stock, $0.001 par value, 50,000,000 shares authorized at December 31, 2023; 0
     shares issued and outstanding at December 31, 2023 and 2022

—

—

Common Stock, $0.001 par value, 500,000,000 shares authorized at December 31, 2023,
     158,757,620 and 153,990,128 shares issued and outstanding at December 31, 2023 and
     2022, respectively

159

154

Additional paid-in-capital

901,259

810,186

Accumulated other comprehensive loss

(916)

(2,899)

Accumulated earnings

8,954

775

Total stockholders’ equity

909,456

808,216

Total liabilities and stockholders’ equity

$   1,191,724

$   1,168,683

 

INTEGRAL AD SCIENCE HOLDING CORP.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

(UNAUDITED)

Three months ended December 31,

Year ended December 31,

(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)

2023

2022

2023

2022

Revenue

$       134,295

$       117,435

$      474,369

$      408,348

Operating expenses:

Cost of revenue (excluding depreciation and amortization shown below)

28,252

21,891

99,352

75,755

Sales and marketing

30,423

28,325

117,989

106,286

Technology and development

19,056

22,280

72,906

76,351

General and administrative

25,961

23,572

111,634

79,654

Depreciation and amortization

14,593

12,811

54,966

50,396

Foreign exchange (gain) loss, net

(501)

1,246

430

4,749

Total operating expenses

117,784

110,125

457,277

393,191

Operating income

16,511

7,310

17,092

15,157

Interest expense, net

(2,489)

(3,194)

(12,236)

(9,053)

Employee retention tax credit

—

—

—

6,981

Net income before income taxes

14,022

4,116

4,856

13,085

(Provision) benefit from income taxes

(3,858)

7,371

2,382

2,288

Net income

$         10,164

$         11,487

$          7,238

$        15,373

Net income per share:

Basic

$             0.06

$             0.07

$           0.05

$           0.10

Diluted

$             0.06

$             0.07

$           0.04

$           0.10

Weighted average shares outstanding:

Basic

158,243,619

153,792,438

156,272,335

154,699,694

Diluted

163,060,805

155,288,725

161,723,131

157,258,083

Other comprehensive income:

Foreign currency translation adjustments

2,772

8,634

1,983

(2,584)

Total comprehensive income

$         12,936

$         20,121

$          9,221

$        12,789

 

INTEGRAL AD SCIENCE HOLDING CORP.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’/MEMBERS’ EQUITY

Members’ Interest

Common Stock

(IN THOUSANDS, EXCEPT UNITS
AND SHARES DATA)

Units

Amount

Shares

Amount

Additional

paid-in

capital

Accumulated

other

comprehensive

income (loss)

Accumulated
earnings

(deficit)

Total members’/
stockholders’ 
equity

Balances at January 1, 2021

134,039,494

$            553,717

—

$                     —

$                     —

$               4,523

$          (126,761)

$            431,479

Repurchase of units

(99,946)

(413)

—

—

—

—

(791)

(1,204)

Units vested

17,486

—

—

—

—

—

—

—

Option exercises

246,369

1,075

—

—

3,360

—

—

4,435

Foreign currency translation
adjustment

—

—

—

—

—

(4,838)

—

(4,838)

Net loss prior to corporate conversion

—

—

—

—

—

—

(37,832)

(37,832)

Conversion to Delaware corporation

(134,203,403)

(554,379)

134,203,403

134

388,860

—

165,385

—

Rounding units/shares as a result of
corporate conversion

—

—

(17)

—

—

—

—

—

Stock-based compensation

—

—

—

—

55,222

—

—

55,222

RSUs vested

—

—

26,931

—

150

—

—

150

Issuance of common stock in
connection with initial public offering

—

—

16,821,330

17

274,340

—

—

274,357

Issuance of common stock for Publica
acquisition

—

—

2,888,889

3

49,628

—

—

49,631

Issuance of common stock for Context
acquisition

—

—

457,959

—

10,391

—

—

10,391

Net loss

—

—

—

—

—

—

(14,600)

(14,600)

Balances at December 31, 2021

—

$                     —

154,398,495

$                  154

$            781,951

$                 (315)

$            (14,600)

$            767,190

RSUs vested

—

—

1,084,966

1

—

—

—

1

Option exercises

—

—

1,586,728

2

7,153

—

—

7,155

Stock-based compensation

—

—

—

—

44,733

—

—

44,733

Foreign currency translation
adjustment

—

—

—

—

—

(2,584)

—

(2,584)

Repurchase of common stock

—

—

(3,080,061)

(3)

(23,652)

—

—

(23,655)

Net income

—

—

—

—

—

—

15,373

15,373

Balances at December 31, 2022

—

$                     —

153,990,128

$                  154

$            810,186

$              (2,899)

$                  775

$            808,216

RSUs and MSUs vested

—

—

3,492,130

4

—

—

—

4

Option exercises

—

—

1,001,793

1

7,988

—

—

7,989

ESPP purchase

—

—

273,569

—

2,306

—

—

2,306

Stock-based compensation

—

—

—

—

80,779

—

—

80,779

Foreign currency translation adjustment

—

—

—

—

—

1,983

—

1,983

Adoption of ASC 326, net of tax

—

—

—

—

—

—

941

941

Net income

—

—

—

—

—

—

7,238

7,238

Balances at December 31, 2023

—

$                     —

158,757,620

$                  159

$            901,259

$                 (916)

$               8,954

$            909,456

 

INTEGRAL AD SCIENCE HOLDING CORP.

CONSOLIDATED STATEMENTS OF CASH FLOWS

Year ended December 31,

(IN THOUSANDS)

2023

2022

Cash flows from operating activities:

Net income

$          7,238

$        15,373

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

54,966

50,396

Stock-based compensation

81,103

44,752

Foreign exchange (gain) loss, net

(484)

5,233

Deferred tax benefit

(21,531)

(8,880)

Amortization of debt issuance costs

463

464

Allowance for credit losses

3,816

1,837

Employee retention tax credit

—

(6,981)

Impairment of assets

33

974

Changes in operating assets and liabilities:

Increase in accounts receivable

(8,148)

(18,581)

Increase in unbilled receivables

(4,685)

(5,830)

Decrease (increase) in prepaid expenses and other current assets

6,418

(10,641)

Increase in operating leases, net

(29)

(852)

Decrease (increase) in other long-term assets

375

(1,057)

Increase in accounts payable and accrued expenses and other long-term liabilities

11,478

6,286

Increase (decrease) in deferred revenue

582

(88)

Increase in due to/from related party

28

62

Net cash provided by operating activities

131,623

72,467

Cash flows from investing activities:

Payment for acquisitions, net of acquired cash

(966)

(1,603)

Purchase of property and equipment

(1,975)

(2,016)

Acquisition and development of internal use software and other

(31,777)

(14,673)

Net cash used in investing activities

(34,718)

(18,292)

Cash flows from financing activities:

Repayment of long-term debt

(145,000)

(35,000)

Repayment of short-term debt

—

(1,816)

Proceeds from the Revolver

75,000

15,000

Proceeds from exercise of stock options

7,989

7,155

Payments for repurchase of common stock

—

(23,655)

Cash received from Employee Stock Purchase Program (ESPP)

3,160

845

Net cash used in financing activities

(58,851)

(37,471)

Net increase in cash, cash equivalents, and restricted cash

38,054

16,704

Effect of exchange rate changes on cash and cash equivalents, and restricted cash

(435)

(3,111)

Cash, cash equivalents, and restricted cash, at beginning of year

89,671

76,078

Cash, cash equivalents, and restricted cash, at end of year

$      127,290

$        89,671

Supplemental Disclosures:

Cash paid during the year for:

Interest

$        11,229

$          8,511

Taxes

$        10,985

$        16,396

Non-cash investing and financing activities:

Property and equipment acquired included in accounts payable

$             431

$               97

Internal use software acquired included in accounts payable

$          1,444

$          1,517

Lease liabilities arising from right of use assets

$          6,282

$        29,624

Supplemental Disclosure Regarding Non-GAAP Financial Information

We use supplemental measures of our performance, which are derived from our consolidated financial information, but which are not presented in our consolidated financial statements prepared in accordance with GAAP. Adjusted EBITDA is the primary financial performance measure used by management to evaluate our business and monitor ongoing results of operations. Adjusted EBITDA is defined as income/loss before depreciation and amortization, stock-based compensation, interest expense, income taxes, restructuring and severance costs, acquisition and integration costs, foreign exchange gains and losses, and other one-time, non-recurring costs. Adjusted EBITDA margin represents the adjusted EBITDA for the applicable period divided by the revenue for that period presented in accordance with GAAP.

We use non-GAAP financial measures to supplement financial information presented on a GAAP basis. We believe that excluding certain items from our GAAP results allows management to better understand our consolidated financial performance from period to period and better project our future consolidated financial performance as forecasts are developed at a level of detail different from that used to prepare GAAP-based financial measures. Moreover, we believe these non-GAAP financial measures provide our shareholders with useful information to help them evaluate our operating results by facilitating an enhanced understanding of our operating performance and enabling them to make more meaningful period-to-period comparisons. Although we believe these measures are useful to investors and analysts for the same reasons they are useful to management, these measures are not a substitute for, or superior to, U.S. GAAP financial measures or disclosures. Our non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.

Reconciliation of historical Adjusted EBITDA and corresponding margin to their most directly comparable GAAP financial measures, net income/loss and corresponding margin are presented below. We encourage you to review the reconciliations in conjunction with the presentation of the non-GAAP financial measures for each of the periods presented. In future fiscal periods, we may exclude such items and may incur income and expenses similar to these excluded items.

Reconciliation of Adjusted EBITDA

Three months ended December 31,

Year ended December 31,

(in thousands, except percentages)

2023

2022

2023

2022

Net income

$       10,164

$       11,487

$         7,238

$      15,373

Depreciation and amortization

14,593

12,811

54,966

50,396

Stock-based compensation

15,462

11,645

81,103

44,752

Interest expense, net

2,489

3,194

12,236

9,053

Provision (benefit) from income taxes

3,858

(7,371)

(2,382)

(2,288)

Restructuring and severance costs

1,054

5,904

4,028

10,321

Acquisition and integration costs

—

118

—

97

Foreign exchange (gain) loss, net

(501)

1,246

430

4,798

Employee retention tax credit

—

—

—

(6,981)

Offering costs, impairments and other costs

396

1,003

1,913

1,058

Adjusted EBITDA

$       47,515

$       40,037

$     159,532

$    126,579

Revenue

$     134,295

$     117,435

$     474,369

$    408,348

Net income margin

8 %

10 %

2 %

4 %

Adjusted EBITDA margin

35 %

34 %

34 %

31 %

 

Stock-Based Compensation 

Three months ended December 31,

Year ended December 31,

(in thousands)

2023

2022

2023

2022

Cost of revenue

$             124

$             249

$             452

$             507

Sales and marketing

5,512

2,871

23,371

13,520

Technology and development

4,104

2,958

17,538

9,937

General and administrative

5,722

5,567

39,742

20,788

Total stock-based compensation

$         15,462

$         11,645

$         81,103

$         44,752

Conference Call and Webcast Information
IAS will host a conference call and live webcast to discuss its fourth quarter and full year 2023 financial results today at 5:00 p.m. ET. To access the live webcast and conference call dial-in, please register under the “News & Events” section of IAS’s investor relations website. A replay will be available on IAS’s investor relations website following the live call: https://investors.integralads.com.

About Integral Ad Science
Integral Ad Science (IAS) is a leading global media measurement and optimization platform that delivers the industry’s most actionable data to drive superior results for the world’s largest advertisers, publishers, and media platforms. IAS’s software provides comprehensive and enriched data that ensures ads are seen by real people in safe and suitable environments, while improving return on ad spend for advertisers and yield for publishers. Our mission is to be the global benchmark for trust, safety, and transparency in digital media quality. For more information, visit integralads.com.

Forward-Looking Statements
This earnings press release contains forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical fact included in this press release are forward-looking statements. Forward-looking statements give our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “anticipate,” “estimate,” “expect,” “project,” “plan,” “intend,” “believe,” “may,” “will,” “should,” “can have,” “likely,” and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. For example, all statements we make relating to our estimated and projected costs, expenditures, cash flows, growth rates and financial results or our plans and objectives for future operations, growth initiatives or strategies are forward-looking statements. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that we expected, including: (i) the adverse effect on our business, operating results, financial condition, and prospects from various macroeconomic factors, including instability in geopolitical or market conditions; (ii) our failure to innovate or make the right investment decisions; (iii) our ability to provide digital or cross-platform analytics; (iv) our failure to maintain or achieve industry accreditation standards; (v) our dependence on integrations with advertising platforms, demand side providers (“DSPs”) and proprietary platforms that we do not control; (vi) our ability to compete successfully with our current or future competitors in an intensely competitive market; (vii) our inability to use software licensed from third parties; (viii) our international expansion; (ix) our ability to expand into new channels; (x) our ability to sustain our profitability and revenue growth rate; (xi) risks that our customers do not pay or choose to dispute their invoices; (xii) risks of material changes to revenue share agreements with certain DSPs; (xiii) our dependence on the overall demand for advertising; (xiv) our ability to effectively manage our growth; (xv) the impact that any acquisitions we have completed in the past and may consummate in the future, strategic investments, or alliances may have on our business, financial condition, and results of operations; (xvi) our ability to successfully execute our international plans; (xvii) the risks associated with the seasonality of our market; (xviii) our ability to maintain high impression volumes; (xix) the difficulty in evaluating our future prospects given our short operating history; (xx) uncertainty in how the market for buying digital advertising verification solutions will evolve; (xxi) interruption by man-made problems such as terrorism, computer viruses, or social disruptions; (xxii) the risk of failures in the systems and infrastructure supporting our solutions and operations; (xxiii) our ability to avoid operational, technical, and performance issues with our platform; (xxiv) risks associated with any unauthorized access to user, customer, or inventory and third-party provider data; (xxv) our ability to provide the non-proprietary technology, software, products, and services that we use; (xxvi) the risk that we are sued by third parties for alleged infringement, misappropriation, or other violation of their proprietary rights; (xxvii) our ability to obtain, maintain, protect, or enforce intellectual property and proprietary rights that are important to our business; (xxviii) our involvement in lawsuits to protect or enforce our intellectual property; (xxix) risks that our employees, consultants, or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers; (xxx) risks that our trademarks and trade names are not adequately protected; (xxxi) the impact of unforeseen changes to privacy and data protection laws and regulation on digital advertising; (xxxii) our ability to maintain our corporate culture; (xxxiii) public health outbreaks, epidemics, pandemics, or other public health crises; (xxxiv) risks posed by earthquakes, fires, floods, and other natural catastrophic events; (xxxv) the risk that a perceived failure to comply with laws and industry self-regulation may damage our reputation; and (xxxvi) other factors disclosed in our filings with the SEC. Given these factors, as well as other variables that may affect our operating results, you should not rely on forward-looking statements, assume that past financial performance will be a reliable indicator of future performance, or use historical trends to anticipate results or trends in future periods.

We derive many of our forward-looking statements from our operating budgets and forecasts, which are based on many detailed assumptions. While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and it is impossible for us to anticipate all factors that could affect our actual results. The forward-looking statements included in this press release are made only as of the date hereof. We undertake no obligation to update or revise any forward- looking statement as a result of new information, future events or otherwise, except as otherwise required by law.

Investor Contact:
Jonathan Schaffer / Lauren Hartman
ir@integralads.com

Media Contact:
press@integralads.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ias-reports-fourth-quarter-and-full-year-2023-financial-results-302073075.html

SOURCE Integral Ad Science, Inc.

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

IQST – iQSTEL and Cycurion Form Exclusive Cybersecurity Partnership to Supercharge Expansion into High-Tech, High-Margin Markets

Published

43 mins ago

on

October 10, 2024

By

NEW YORK, Oct. 10, 2024 /PRNewswire/ — iQSTEL Inc. (OTCQX: IQST), a dynamic leader in telecommunications, fintech, electric vehicle (EV), and AI-driven solutions, is thrilled to announce an exclusive partnership with Cycurion, INC. This strategic collaboration will allow iQSTEL to offer Cycurion’s top-tier cybersecurity products exclusively to the U.S. telecommunications industry, while also expanding into other sectors internationally. Leveraging iQSTEL’s global presence across 17 time zones, from California to Melbourne, and 7 offices worldwide, this partnership is set to unleash a new wave of high-margin, high-tech offerings for telecommunications clients in Europe, Latin America, the Middle East, and the United States, all while delivering cutting-edge cybersecurity solutions to an increasingly challenging market.

A Transformational Move for iQSTEL.

This partnership is a bold leap forward in iQSTEL’s ongoing journey to diversify and expand its portfolio. Over the past few years, iQSTEL has meticulously built a strong business platform, earning the trust of its global customer base. Now, with this deep foundation in place, iQSTEL is perfectly positioned to cross-sell high-margin, high-tech products such as Fintech, EV, and AI-based services. With this partnership, iQSTEL is adding cybersecurity to its offerings, further solidifying its presence in emerging markets.

Leandro Iglesias, CEO of iQSTEL, stated:

“This partnership with Cycurion couldn’t have come at a more pivotal time for iQSTEL. We’ve earned the trust of our clients by building a strong foundation, and now we’re amplifying that strength by offering the high-tech solutions they need, especially in cybersecurity. We’re delivering future-proof, high-margin services that not only meet the demands of today’s digital landscape but also cement our leadership in these rapidly growing sectors. Investors should take note: we’re just getting started.”

The partnership is laser-focused on addressing critical challenges faced by telecom operators, including meeting stringent security compliance requirements, navigating a global shortage of cybersecurity professionals, and mitigating the increasing number of data breaches. By combining iQSTEL’s operational excellence with Cycurion’s advanced cybersecurity expertise, the companies are poised to deliver unparalleled security solutions to telecom customers, turning these challenges into high-margin growth opportunities.

A Next-Generation Cybersecurity Strategy

Cycurion’s portfolio of cybersecurity services, powered by artificial intelligence (AI), includes 24/7 monitoring, advanced threat detection, incident response, vulnerability assessments, and compliance management. The AI-driven platform continuously adapts to emerging threats, enhancing its ability to detect and respond to cyber risks in real time. Trusted by government agencies such as FEMA, TSA, and the US Courts, Cycurion’s proven track record of delivering world-class security services will empower iQSTEL to enhance its product lineup, further increasing customer loyalty and securing long-term revenue growth.

This partnership is expected to drive significant revenue growth for iQSTEL, tapping into the rapidly expanding global cybersecurity market, projected to reach $376 billion by 2029.

Kevin Kelly, CEO of Cycurion, commented:

“Our partnership with iQSTEL opens up tremendous opportunities. We’re bringing our cybersecurity expertise to iQSTEL’s already strong business platform, enabling them to offer next-level protection to telecom clients. This isn’t just about security—it’s about enhancing customer confidence, increasing profitability, and ultimately growing both companies’ market share in the cybersecurity space.”

Key Benefits for iQSTEL Customers and Investors:

24/7/365 Threat and Risk Management: Immediate, real-time protection from the most advanced cybersecurity threats.Revenue-Driving Public Confidence: Enhanced security measures lead to greater trust from customers, preventing breaches that could undermine public and stakeholder confidence.Privacy Protection & Compliance: Strengthening privacy safeguards while ensuring clients meet evolving regulatory standards.Volume Pricing & Financial Advantage: iQSTEL’s purchasing power ensures significantly lower cybersecurity costs for customers, while maintaining a competitive edge.Expanding into High-Growth Sectors: With Cycurion’s services, iQSTEL will continue expanding its reach into high-margin markets such as Fintech, EV, and AI, reinforcing its leadership position.

Empowering the Future with iQSTEL’s Strong Business Platform.

This partnership exemplifies iQSTEL’s long-term strategy: leveraging the strong foundation of its customer relationships to seamlessly introduce high-tech, high-margin products. The trust that iQSTEL’s customers place in its services positions the company to capitalize on massive opportunities in rapidly growing industries like cybersecurity, fintech, electric vehicles, and AI.

Investors are invited to join iQSTEL on this exciting journey. With a projected revenue of $290 million for FY-2024 and plans to continue delivering innovative solutions, iQSTEL’s growth trajectory is stronger than ever. This partnership with Cycurion sets the stage for significant revenue expansion and positions iQSTEL as a major player in the high-margin tech markets of the future.

About Cycurion Inc.

Cycurion, headquartered in McLean, Virginia, is a premier cybersecurity provider specializing in multi-layered defense systems, monitoring, incident response, and compliance management. With a strong leadership team and a growing portfolio of services, Cycurion is dedicated to protecting its clients’ most valuable digital assets across both the public and private sectors.

Cycurion’s leadership team brings a wealth of experience from various sectors, including technology, finance, and cybersecurity:

Emmit McHenry, Chairman: Founder of NetCom Solutions International, which grew to nearly $300 million in revenue within six years, with operations in the U.S., UK, and South Africa. He also founded Network Solutions, which was later sold to SAIC. McHenry is a U.S. Marine Corps service-disabled veteran and has held executive positions at major firms like Allstate Insurance.Kevin Kelly, CEO: Former CEO of Halo Privacy, a cybersecurity company, and Heidrick & Struggles, a leading executive search firm. He also served as CEO and President of North America for APP – Asia Pulp and Paper. Kelly holds an MBA from Duke University’s Fuqua School of Business.Alvin McCoy, CFO: Former Managing Partner of Quantum Capital Partners and President & CEO of The McCoy Group, LLC. McCoy managed over $75 billion in new debt origination at Merrill Lynch and has served on the boards of financial institutions with assets up to $5 billion. He holds an MBA in Finance from Duke University.

Key Facts About Cycurion:

Headquarters: McLean, VirginiaR&D Center: Tel Aviv, IsraelStaff: 80 highly skilled employees, with an impressive list of industry certificationsDoD Cleared Facilities30% of employees hold Top Secret security clearances45 large active contracts2023 Year-End Revenue: $19.6 million

Cycurion Security Platform: Powered by artificial intelligence (AI), Cycurion has developed an enhanced, multi-layered SaaS solution designed to protect clients’ digital assets while minimizing false positives. This AI-driven platform continuously improves its threat detection and incident response capabilities, delivering effective defense in an increasingly complex and evolving cyber landscape.

About iQSTEL (Updated Oct. 2024):

iQSTEL Inc. (OTC-QX: IQST) (www.iQSTEL.com) is a US-based multinational publicly listed company in the final stages of the path to becoming listed on NASDAQ. With FY2023 revenues of $144 million and a forecasted $290 million in revenue, alongside positive operating income of seven digits for FY-2024, iQSTEL is positioning itself for explosive growth. iQSTEL’s mission is to serve basic human needs in today’s modern world by making essential tools accessible, regardless of race, ethnicity, religion, socioeconomic status, or identity. The company recognizes that modern human needs such as physiological, safety, relationship, esteem, and self-actualization are marginalized without access to ubiquitous communications, financial freedom, clean, affordable mobility, and information.

iQSTEL has been building a strong business platform with its customers, and by leveraging this trust, the company is now beginning to sell high-tech, high-margin products across its divisions. iQSTEL is strategically positioned to achieve $1 billion in revenue by 2027 through organic growth, acquisitions, and high-margin product expansion.

Telecommunications Services Division (Communications):
Includes VoIP, SMS, International Fiber-Optic, Proprietary Internet of Things (IoT), and a Proprietary Mobile Portability Blockchain Platform.Fintech Division (Financial Freedom):
Provides remittance services, top-up services, a MasterCard Debit Card, US bank accounts (no SSN required), and a Mobile App.Electric Vehicles (EV) Division (Mobility):
Offers Electric Motorcycles and plans to launch a Mid-Speed Car.Artificial Intelligence (AI) Services Division (Information and Content):
Features an enriched, immersive white-label proprietary AI-Enhanced Metaverse platform that provides access to products, services, entertainment, information, and customer support in a virtual 3D interface.Cybersecurity Services:
Through a new partnership with Cycurion, iQSTEL will offer advanced cybersecurity solutions, including 24/7 monitoring, threat detection, incident response, vulnerability assessments, and compliance management, providing essential protection to telecommunications clients and beyond.

iQSTEL has completed 11 acquisitions since June 2018 and continues to develop an active pipeline of potential future acquisitions, further expanding its suite of products and services both organically and through mergers and acquisitions.

Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and iQSTEL Inc. undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Company Website
www.iqstel.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/iqst—iqstel-and-cycurion-form-exclusive-cybersecurity-partnership-to-supercharge-expansion-into-high-tech-high-margin-markets-302272356.html

SOURCE iQSTEL

Continue Reading

Technology

CULT Food Science Subsidiary Further Foods Welcomes New Head of Sales and Marketing

Published

43 mins ago

on

October 10, 2024

By

Kevin Ryan joins Noochies! team to drive growth and innovation

TORONTO, Oct. 10, 2024 /PRNewswire/ – CULT Food Science Corp. (“CULT” or the “Company”) (CSE: CULT) (OTC: CULTF) (FRA: LN00), a disruptive food technology platform pioneering the commercialization of lab grown meat and cellular agriculture to reshape the global food industry, is pleased to announce that Kevin Ryan will be joining its subsidiary, Further Foods Inc., as the Head of Sales and Marketing for its innovative pet food brand, Noochies!

Key Takeaways:

Kevin brings a wealth of pet food industry experience to Noochies! Head of Sales and Marketing roleNoochies! brand is poised for retail sales growth both in North America and internationally

In his new role, Kevin will lead the development and implementation of all sales and marketing strategies aimed at achieving revenue targets and expanding distribution. He will guide the growth of the Noochies! brand into new markets and channels, while building and maintaining strong relationships with key clients, distributors and retail partners. Additionally, he’ll spearhead all consumer and digital marketing initiatives, overseeing the development and execution of the brand’s positioning, messaging and campaigns. Working closely with the Company’s CEO, Kevin will also focus on driving growth through direct-to-consumer platforms, including the company’s own website and 3rd party marketplaces like Amazon and Chewy.

No stranger to the pet industry, Kevin previously served as the International Sales Manager for Midwestern Pet Foods, Inc. While there, he managed the brand’s presence, sales channel and profitability outside of the United States through proactive and assertive marketing initiatives. Prior to that, he served as the Global Marketing Director for TOP 1 Oil Products Co. USA, where he expanded the brand’s global presence, sales channels and profitability across 40 international accounts, while also setting five Guinness World Records.

Management Commentary

“We are thrilled to welcome Kevin to the Noochies! team,” commented Mitchell Scott, CEO of CULT Food Science. “His expertise and ability to identify market opportunities, combined with his strategic approach to both sales and marketing, will be instrumental in driving our growth and establishing Noochies! as a top brand in the global specialty pet market.”

About CULT Food Science

CULT Food Science is a disruptive food technology platform pioneering the commercialization of lab grown meat and cellular agriculture to reshape the global food industry. CULT’s robust portfolio of investments in cutting-edge, venture-backed cellular agriculture and lab-grown meat companies provides widespread investor access to the future of food. Backed by a team of experts with extensive experience in food technology and launching consumer food products, CULT is committed to being at the forefront of the food revolution.

About Further Foods

Further Foods is revolutionizing pet nutrition through its innovative brand, Noochies! Noochies! leverages advanced cellular agriculture technologies to create pet food products with superior nutrition profiles and ethical standards. Noochies! recently introduced the world’s first freeze-dried, high-protein, nutrient-rich pet treats made without factory farming. Noochies! products are currently available for sale in the United States and Canada at select retailers and online at https://www.noochies.co/.

Additional information can be found by viewing the Company’s website at cultfoodscience.com or its regulatory filings on sedar.com.

On behalf of the Board of Directors of the Company,

CULT FOOD SCIENCE CORP.

“Mitchell Scott”
Mitchell Scott, Chief Executive Officer

Forward-Looking Information:

Information set forth in this news release may involve forward-looking statements. Forward-looking statements are statements that relate to future, not past, events. In this context, forward-looking statements often address a company’s expected future business and financial performance, and often contain words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, and “intend”, statements that an action or event “may”, “might”, “could”, “should”, or “will” be taken or occur, or other similar expressions. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include but are not limited to the following risks: those associated with marketing and sale of securities; the need for additional financing; reliance on key personnel; the potential for conflicts of interest among certain officers or directors with certain other projects; and the volatility of common share price and volume. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made and except as required by law, the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change. Investors are cautioned against attributing undue certainty to forward-looking statements. For further information on risk, investors are advised to see the Company’s MD&A and other disclosure filings with the regulators which are found at sedar.com.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cult-food-science-subsidiary-further-foods-welcomes-new-head-of-sales-and-marketing-302272590.html

SOURCE Cult Food Science Corp

Continue Reading

Technology

Clario and PathAI Collaborate to Deliver Integrated Solution for GI Clinical Trials

Published

43 mins ago

on

October 10, 2024

By

Partnership combines revolutionary digital pathology and endoscopy solutions, enhancing drug development for IBD and other GI disorders

Strategic Partnership: Streamlined, single-vendor solution improves diagnostic accuracy, boosts efficiency, and enables reliable turnaround times in gastrointestinal (GI) clinical trials.

Advanced GI Solutions: Enhances trial efficiency with AI-powered solutions, including reading for ulcerative colitis (UC) from Clario and histopathology services from PathAI.

Integrated Workflow: Combines endoscopic and histopathology endpoints with simplified processes for CROs, sponsors, and investigational sites.

PHILADELPHIA, Oct. 10, 2024 /PRNewswire/ — Clario, a leading provider of endpoint data solutions to the clinical trials industry, is excited to announce a strategic partnership with PathAI, a leader in AI-powered digital pathology solutions aimed at improving diagnostic accuracy and efficiency. This collaboration offers a single-vendor solution for efficient anatomical pathology services and next-generation video endoscopy analysis.

This co-delivery model streamlines endoscopic and histopathology endpoints to improve efficiency in global GI studies. CROs and sponsors will benefit from an end-to-end process that covers training, logistics, tissue processing, slide digitization, image analysis, and data transfers all with the medical and scientific oversight of our experts. Sites will experience simplified workflows with improved training, reporting, and document management.

“At Clario we have long been at the forefront of supporting GI clinical trials, and we are excited to augment our strengths with PathAI’s capabilities in the area of discovery and patient care,” said Marcela Vieira, M.D., Clario’s Medical Director of Gastroenterology. “The combination of endoscopy and histopathology promises to unlock new avenues for clinical research, and we are proud to be in this leadership position with our partners at PathAI.”

Clario has extensive experience in GI trials, having supported over 130 studies through advanced imaging solutions like endoscopy, MRI, and ultrasound. Their scientists and technologies help reduce site burden and enhance trial efficiency with AI-supported reading for UC and HD-video endoscopy support.

PathAI bolsters the partnership with its expert GI pathologist network and cutting-edge anatomical pathology services while optimizing specimen handling and histological assessments. Their AI-powered tools enhance UC assessment, minimize variability in histological scoring, and expedite biomarker discovery.

“We’re thrilled to partner with Clario to provide a cutting-edge solution for IBD clinical trials,” said Matt Grow, Chief Business Officer & President of Biopharma at PathAI. “Our collaboration will offer an integrated approach in histology and endoscopy for assessing therapeutic efficacy, accelerating biomarker discovery and therapy development in IBD.”

About Clario

Clario is a leading provider of endpoint data solutions to the clinical trials industry, generating high-quality clinical evidence for our pharmaceutical, biotech, and medical device partners. We offer comprehensive evidence generation solutions that combine eCOA, cardiac solutions, medical imaging, precision motion, and respiratory endpoints.

For more than 50 years, Clario has delivered deep scientific expertise and broad endpoint technologies to help transform lives around the world. Our endpoint data solutions have supported over 26,000 clinical trials in more than 100 countries. Our global team of science, technology, and operational experts have supported over 60% of all FDA drug approvals since 2012.

For more information, visit Clario.com or follow on LinkedIn.

About PathAI

Headquartered in Boston, PathAI is the only AI-focused technology company providing comprehensive precision pathology solutions, from wet lab services to algorithm deployment for clinical trials and laboratory use. Rigorously trained and validated with over 15 million annotations, its AI-powered models optimize pathology sample analysis, improving efficiency and accuracy in interpretation while gauging therapeutic efficacy and accelerating drug development for complex diseases.

For more information, visit pathai.com 

Media Contact:
media@clario.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/clario-and-pathai-collaborate-to-deliver-integrated-solution-for-gi-clinical-trials-302271866.html

SOURCE Clario

Continue Reading

Trending